Unprecedented advances in tumor management have been made possible by therapeutic mAb-mediated masking of inhibitory ‘‘checkpoint” receptors (PD-1, KIRs, and NKG2A) [75, 78]. The gene discussed is KLRC1; the disease is neoplasm.